TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy - Poll - MDSpire

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • By

  • Carolina Kessler

  • Melanie von Brandenstein

  • Niklas Klümper

  • Philipp Krausewitz

  • Enno Storz

  • Constantin Rieger

  • Laurenz Sperber

  • Pia Paffenholz

  • Yuri Tolkach

  • Ralph Wirtz

  • Markus Eckstein

  • Axel Heidenreich

  • Richard Weiten

  • September 1, 2025

  • 0 min

Share

Original Source(s)

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • by Carolina Kessler, Melanie von Brandenstein, Niklas Klümper, Philipp Krausewitz, Enno Storz, Constantin Rieger, Laurenz Sperber, Pia Paffenholz, Yuri Tolkach, Ralph Wirtz, Markus Eckstein, Axel Heidenreich, Richard Weiten

  • September 1, 2025

Related Content

Enhanced recovery after surgery nursing improves postoperative outcomes in laparoscopic radical nephrectomy: a cumulative meta-analysis

Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy

Molecular Profiling, Prognostic Insights, and Immune Landscape Evaluation of NUDT16 in Clear Cell Renal Cell Carcinoma